Innogy to push windfarms, electric car charging in U.S.: paper
- Wall Street falls ahead of inauguration
- IBM (IBM) Tops Q4 EPS by 13c, FY17 EPS Guidance Beats Consensus
- American Express (AXP) Misses Q4 EPS by 7c, FY17 EPS Guidance Tops Views at Mid-Poinit
- Skyworks Solutions (SWKS) Tops Q1 EPS by 3c, Offers Q2 Guidance, Announces Buyback
- Synergy Pharma (SGYP) Trulance (Plecanatide) Approved by FDA
Peter Terium, chief executive of German power supplier RWE and Carsten Kengeter (L), CEO of Deutsche Boerse pose with a bull, symbol of successful burse trading, before the first trading day of shares of RWE's new ecological daughter Innogy at the stock e
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
FRANKFURT (Reuters) - Innogy
"We want to invest around 6.5 billion euros between 2016 and 2018," Chief Executive Peter Terium told the paper, adding that investments will include grid networks and infrastructure but also wind farms in Germany, Poland, the Netherlands and electric car charging stations in the United States.
Innogy, which was spun off from German energy utility RWE with a stock market listing this week, sees an opportunity to push electric car charging stations thanks to regulatory backing.
"Three weeks ago we persuaded Californian authorities to accept the German norms and standards for electric car charging stations," Terium said, adding that this may provide an opportunity to partner with German carmakers to help them expand electric car sales in the United States.
In May, Reuters reported that RWE was on the lookout for partnerships with auto makers in the area of electric cars.
Innogy has already installed more than 3,100 electric car charging stations in Germany.
(Reporting by Edward Taylor; editing by Susan Thomas)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Uber to pay $20 million to settle U.S. allegations it misled drivers about earnings
- Trump taps NFL owner Woody Johnson as ambassador to UK
- U.S. health agency tells Grassley there is no EpiPen settlement yet